ALX Oncology Holdings Inc. announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results